Cover Image

Biomarkers for the detection and risk stratification of aggressive prostate cancer

Current strategies for the clinical management of prostate cancer are inadequate for a precise risk stratification between indolent and aggressive tumors. Recently developed tissue-based molecular biomarkers have refined the risk assessment of the disease. The characterization of tissue biopsy compo...

Full description

Saved in:
Bibliographic Details
Main Authors: Eickelschulte, Samaneh (Author) , Riediger, Anja Lisa (Author) , Angeles, Arlou Kristina J. (Author) , Janke, Florian (Author) , Duensing, Stefan (Author) , Sültmann, Holger (Author) , Görtz, Magdalena (Author)
Format: Article (Journal)
Language:English
Published: 11 December 2022
In: Cancers
Year: 2022, Volume: 14, Issue: 24, Pages: 1-24
ISSN:2072-6694
DOI:10.3390/cancers14246094
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers14246094
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/14/24/6094
Get full text
Author Notes:Samaneh Eickelschulte, Anja Lisa Riediger, Arlou Kristina Angeles, Florian Janke, Stefan Duensing, Holger Sültmann and Magdalena Görtz
Description
Summary:Current strategies for the clinical management of prostate cancer are inadequate for a precise risk stratification between indolent and aggressive tumors. Recently developed tissue-based molecular biomarkers have refined the risk assessment of the disease. The characterization of tissue biopsy components and subsequent identification of relevant tissue-based molecular alterations have the potential to improve the clinical decision making and patient outcomes. However, tissue biopsies are invasive and spatially restricted due to tumor heterogeneity. Therefore, there is an urgent need for complementary diagnostic and prognostic options. Liquid biopsy approaches are minimally invasive with potential utility for the early detection, risk stratification, and monitoring of tumors. In this review, we focus on tissue and liquid biopsy biomarkers for early diagnosis and risk stratification of prostate cancer, including modifications on the genomic, epigenomic, transcriptomic, and proteomic levels. High-risk molecular alterations combined with orthogonal clinical parameters can improve the identification of aggressive tumors and increase patient survival.
Item Description:Gesehen am 21.02.2023
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers14246094

Similar Items